5-methyl,5'-acetyl,2,2'-bithiophene | 32426-05-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 双噻吩和低聚噻吩
• 英文名称: 5-methyl,5'-acetyl,2,2'-bithiophene
• 英文别名: 5'-Methyl-5-acetyl-2,2'-dithienyl；1-(5'-methyl-2,2'-bithiophene-5-yl)ethanone；1-[5-(5-Methylthiophen-2-yl)thiophen-2-yl]ethanone
• CAS: 32426-05-4
• 化学式: C₁₁H₁₀OS₂
• 分子量: 222.332
• InChiKey: FYKMNTKJTFSEKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  73.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,2-联噻吩-5-乙醛 、 5-methyl,5'-acetyl,2,2'-bithiophene 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 以90%的产率得到(E)-3-[2,2']Bithiophenyl-5-yl-1-(5'-methyl-[2,2']bithiophenyl-5-yl)-propenone
  参考文献：
  名称：

  生物活性噻吩衍生物。四、噻吩系列不饱和酮的合成及抗病毒活性

  摘要：

  ar R = C~Hs; R' = 5'-甲基-2,2'-二噻吩基-5-基；b: R = 2-呋喃基；R~=2,2~-二噻吩！-5-基；c: R = 2-呋喃基；R' = 5'-methyl-2~2'-dithienyl-5-y!; d：R = 2-噻吩基；R~=5'-甲基-2，2'二噻吩基-5-yi；e: R = 2-噻吩基；R' = 2,2'-二噻吩基-5-基；f: R = 2,2'-二噻吩；R' = 2-thienyi; g：R = 2,2'-二噻吩基-5-基；R' = 5'-methvl-2.2'-dithienvl-5-vl: h: R = 5 ~methyl-2,2'-dithienyl-5-yl;* i: R = 5'~methyl-2,2' -dithieny!-5-yl; R' = 2-呋喃基；j：R = 5'methyl-2,2'-dithienyl-5-y!；R'=2-噻吩基；k：R

  DOI：

  10.1007/bf00762027
• 作为产物：
  描述：

  2-甲基噻吩 、 2-乙酰基-5-溴噻吩 在 C₄₂H₃₆Cl₂N₂Pd 、 potassium carbonate 、 三甲基乙酸 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 12.0h， 以97%的产率得到5-methyl,5'-acetyl,2,2'-bithiophene
  参考文献：
  名称：

  刚性α-二亚胺钯配合物作为噻吩和杂芳基溴化物的直接 CH 芳基化预催化剂

  摘要：

  描述了由刚性α-二亚胺钯配合物促进的噻吩的直接 CH 杂芳基化。这种方法表现出广泛的底物范围和官能团耐受性，并继续形成区域选择性产物。

  DOI：

  10.1016/j.inoche.2022.109403

文献信息

• Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
  申请人：Altenbach J. Robert

  公开号：US20050272728A1

  公开（公告）日：2005-12-08

  Compounds of formula (I) wherein R 1 or R 2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L 2 and L 3 , to a heteroaromatic core, and X, X′, Y, Y′, Z, Z′, R 1 , R 2 , R 3 , R 3a , R 3b , R 4 , R 5 , L, L 2 , and L 3 are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

  式（I）的化合物，其中R1或R2是直接连接或通过连接物连接的芳香或非芳香环，如由L2和L3表示，连接到杂环核心，以及X、X'、Y、Y'、Z、Z'、R1、R2、R3、R3a、R3b、R4、R5、L、L2和L3如本文所定义，可用于治疗由组胺-3受体配体预防或改善的病症或疾病。还公开了包含组胺-3受体配体的药物组合物，使用这类化合物和组合物的方法，以及制备符合式（I）范围内化合物的方法。
• Palladium‐Catalysed Direct C‐H Activation/Arylation of Heteroaromatics: An Environmentally Attractive Access to Bi‐ or Polydentate Ligands
  作者：Fazia Derridj、Aditya L. Gottumukkala、Safia Djebbar、Henri Doucet

  DOI：10.1002/ejic.200800143

  日期：2008.6

  Bi- or polydentate ligands based on heterocycles can be easily prepared by palladium-catalysed C–H bond activation of heteroaromatics followed by heteroarylation with heteroaryl bromides. A variety of heteroaromatics such as furans, thiophenes, pyridines, thiazoles or oxazole derivatives have been employed and moderate to good yields were generally obtained using the air-stable complex [PdCl(dppb)(C3H5)]

  基于杂环的双齿或多齿配体可以很容易地通过钯催化的杂芳烃的 C-H 键活化，然后用杂芳基溴化物进行杂芳基化来制备。已经使用了多种杂芳烃，例如呋喃、噻吩、吡啶、噻唑或恶唑衍生物，并且使用空气稳定的络合物 [PdCl(dppb)(C3H5)] 作为催化剂通常可以获得中等至良好的产率。可以容忍杂芳烃上的一系列功能，例如乙酰基、甲酰基、酯或腈。（© Wiley-VCH Verlag GmbH & Co. KGaA，69451 Weinheim，德国，2008）
• Thiophene Based Europium β-Diketonate Complexes: Effect of the Ligand Structure on the Emission Quantum Yield
  作者：Christelle Freund、William Porzio、Umberto Giovanella、Francesco Vignali、Mariacecilia Pasini、Silvia Destri、Agnieszka Mech、Sebastiano Di Pietro、Lorenzo Di Bari、Placido Mineo

  DOI：10.1021/ic1021164

  日期：2011.6.20

  photophysical characterization, together with solid state and solution structure analysis, of a series of europium complexes based on β-diketonate ligands are reported. The Eu(III) complex emission, specifically its photoluminescence quantum yield (PL-QY), can be tuned by changing ligands which finely modifies the environment of the metal ion. Steady-state and time-resolved emission spectroscopy and

  报道了一系列基于β-二酮酸酯配体的of配合物的合成，分子和光物理表征，以及固态和溶液结构分析。Eu（III）配合物的发射，特别是其光致发光量子产率（PL-QY），可以通过改变配体来进行调节，这些配体可以精细地修饰金属离子的环境。报告了稳态和时间分辨发射光谱以及整体PL-QY测量，并且与某些选定化合物的晶体结构中观察到的几何特征有关。此外，基于与其他镧系元素的类似络合物的顺磁NMR被用于证明溶解后存在显着的结构重组，这证明了所观察到的固相和溶液态发射性质的差异。
• [EN] BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS<br/>[FR] AMINES À SUBSTITUTION BICYCLIQUE AYANT DES SUBSTITUANTS MONOCYCLIQUES À SUBSTITUTION CYCLIQUE
  申请人：ABBOTT LAB

  公开号：WO2005113551A1

  公开（公告）日：2005-12-01

  Compounds of formula (I) wherein R1 or R2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L2 and L3, to a heteroaromatic core, and X, X', Y, Y', Z, Z', R1, R2, R3, R3a, R3b, R4, R5, L, L2, and L3 are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

  公式（I）的化合物中，其中R1或R2是芳香或非芳香环，直接连接或通过连接剂L2和L3连接到杂环芳香核心，而X，X'，Y，Y'，Z，Z'，R1，R2，R3，R3a，R3b，R4，R5，L，L2和L3如本文所定义，可用于治疗由组胺-3受体配体预防或改善的疾病或症状。还公开了包含组胺-3受体配体的制药组合物，使用这些化合物和组合物的方法，以及制备公式（I）范围内的化合物的方法。
• In vitro studies on a class of quinoline containing histamine H3 antagonists
  作者：Huaqing Liu、Robert J. Altenbach、Gilbert J. Diaz、Arlene M. Manelli、Ruth L. Martin、Thomas R. Miller、Timothy A. Esbenshade、Jorge D. Brioni、Marlon D. Cowart

  DOI：10.1016/j.bmcl.2010.04.045

  日期：2010.6

  A series of quinoline containing histamine H-3 antagonists is reported herein. These analogs were synthesized via the Friedlander quinoline synthesis between an aminoaldehyde intermediate and a methyl ketone allowing for a wide diversity of substituents at the 2-position of the quinoline ring. (C) 2010 Elsevier Ltd. All rights reserved.